Paper30596398
Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
Luedtke DA and 7 others. J Cell Mol Med, 2018. Cited by 54 papers, by iCite.
Cite this record
ConductScience Library. Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1. Papers, record 30596398. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30596398
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Karyopherins | Major topic |
| Leukemia, Myeloid, Acute | Major topic |
| Myeloid Cell Leukemia Sequence 1 Protein | Major topic |
| Proto-Oncogene Proteins c-bcl-2 | Major topic |
| Receptors, Cytoplasmic and Nuclear | Major topic |
| Adult | |
| Aged | |
| Apoptosis | |
| Bridged Bicyclo Compounds, Heterocyclic | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Drug Resistance, Neoplasm | |
| Drug Synergism | |
| Female | |
| Gene Expression Regulation, Neoplastic | |
| Humans | |
| Hydrazines | |
| Male | |
| Middle Aged | |
| Sulfonamides | |
| Triazoles | |
| Exportin 1 Protein |
Source PubMed
References53
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 15361652 | Detection of mycoplasma contaminations. | Methods Mol Biol | 2005 | https://conductscience.org/library/papers/15361652 | PubMed |
| 2 | 24451410 | BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. | Leukemia | 2014 | https://conductscience.org/library/papers/24451410 | PubMed |
| 3 | 27166183 | Inhibition of CHK1 enhances cell death induced by the Bcl-2-selective inhibitor ABT-199 in acute myeloid leukemia cells. | Oncotarget | 2016 | https://conductscience.org/library/papers/27166183 | PubMed |
| 4 | 27520294 | Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. | Cancer Discov | 2016 | https://conductscience.org/library/papers/27520294 | PubMed |
| 5 | 9150352 | The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines. | Leuk Res | 1997 | https://conductscience.org/library/papers/9150352 | PubMed |
| 6 | 18097445 | The BCL-2 protein family: opposing activities that mediate cell death. | Nat Rev Mol Cell Biol | 2008 | https://conductscience.org/library/papers/18097445 | PubMed |
| 7 | 12783855 | Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. | Genes Dev | 2003 | https://conductscience.org/library/papers/12783855 | PubMed |
| 8 | 9384386 | CRM1 is responsible for intracellular transport mediated by the nuclear export signal. | Nature | 1997 | https://conductscience.org/library/papers/9384386 | PubMed |
| 9 | 11260076 | In vivo suppression of Bcl-XL expression facilitates chemotherapy-induced leukaemia cell death in a SCID/NOD-Hu model. | Br J Haematol | 2001 | https://conductscience.org/library/papers/11260076 | PubMed |
| 10 | 15687366 | GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. | J Natl Cancer Inst | 2005 | https://conductscience.org/library/papers/15687366 | PubMed |
| 11 | 7845007 | Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C. | Leukemia | 1995 | https://conductscience.org/library/papers/7845007 | PubMed |
| 12 | 19082467 | The expression of CRM1 is associated with prognosis in human osteosarcoma. | Oncol Rep | 2009 | https://conductscience.org/library/papers/19082467 | PubMed |
| 13 | 27103402 | Binding of Released Bim to Mcl-1 is a Mechanism of Intrinsic Resistance to ABT-199 which can be Overcome by Combination with Daunorubicin or Cytarabine in AML Cells. | Clin Cancer Res | 2016 | https://conductscience.org/library/papers/27103402 | PubMed |
| 14 | 24346116 | Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia. | Cancer Discov | 2014 | https://conductscience.org/library/papers/24346116 | PubMed |
| 15 | 18495871 | An essential role for MCL-1 in ATR-mediated CHK1 phosphorylation. | Mol Biol Cell | 2008 | https://conductscience.org/library/papers/18495871 | PubMed |
| 16 | 20540941 | Mcl-1; the molecular regulation of protein function. | FEBS Lett | 2010 | https://conductscience.org/library/papers/20540941 | PubMed |
| 17 | 19088047 | A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/19088047 | PubMed |
| 18 | 28336527 | A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. | Blood | 2017 | https://conductscience.org/library/papers/28336527 | PubMed |
| 19 | 23970380 | Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. | Blood | 2013 | https://conductscience.org/library/papers/23970380 | PubMed |
| 20 | 26202935 | Activity of a selective inhibitor of nuclear export, selinexor (KPT-330), against AML-initiating cells engrafted into immunosuppressed NSG mice. | Leukemia | 2016 | https://conductscience.org/library/papers/26202935 | PubMed |
Cited by44
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 54 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42495755 | XPO1: From basic research to clinical treatment (Review). | Oncol Rep | 2026 | https://conductscience.org/library/papers/42495755 | PubMed |
| 41899095 | Resistance to Targeted Therapy in AML: Current Challenges and Emerging Treatment Strategies. | J Clin Med | 2026 | https://conductscience.org/library/papers/41899095 | PubMed |
| 41608989 | Targeting MCL-1 and MAPK overcomes venetoclax resistance in FLT3-ITD-positive AML cells harbouring activating PTPN11 (SHP-2) mutations. | Br J Haematol | 2026 | https://conductscience.org/library/papers/41608989 | PubMed |
| 40955793 | Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine. | Mol Oncol | 2026 | https://conductscience.org/library/papers/40955793 | PubMed |
| 40804253 | Comprehensive view on chemotherapy-free management of acute myeloid leukemia by using venetoclax in combination with targeted and/or immune therapies. | Cell Death Discov | 2025 | https://conductscience.org/library/papers/40804253 | PubMed |
| 40463909 | Selinexor in acute myeloid leukemia: therapeutic applications and current challenges. | Front Pharmacol | 2025 | https://conductscience.org/library/papers/40463909 | PubMed |
| 40100393 | Promising activity of Selinexor in the treatment of a patient with refractory NUP98-NSD1+/FLT3-ITD + acute myeloid leukemia. | Ann Hematol | 2025 | https://conductscience.org/library/papers/40100393 | PubMed |
| 40001478 | XPO1/Exportin-1 in Acute Myelogenous Leukemia; Biology and Therapeutic Targeting. | Biomolecules | 2025 | https://conductscience.org/library/papers/40001478 | PubMed |
| 39780285 | ONC213: a novel strategy to resensitize resistant AML cells to venetoclax through induction of mitochondrial stress. | J Exp Clin Cancer Res | 2025 | https://conductscience.org/library/papers/39780285 | PubMed |
| 39749030 | Selinexor in combination with venetoclax and decitabine in patients with refractory myelodysplastic syndrome previously exposed to hypomethylating agents: three case reports. | Front Oncol | 2024 | https://conductscience.org/library/papers/39749030 | PubMed |
| 39352544 | A review and perspective paper: Ras oncogene gets modest, from kingpin to mere henchman. | Cell Mol Life Sci | 2024 | https://conductscience.org/library/papers/39352544 | PubMed |
| 39307725 | [The clinical safety and efficacy of selinexor combined with venetoclax and azactitidine induction therapy in relapsed and refractory acute myeloid leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2024 | https://conductscience.org/library/papers/39307725 | PubMed |
| 38987275 | The RNA helicases DDX19A/B modulate selinexor sensitivity by regulating MCL1 mRNA nuclear export in leukemia cells. | Leukemia | 2024 | https://conductscience.org/library/papers/38987275 | PubMed |
| 38266099 | The Imipridone ONC213 Targets α-Ketoglutarate Dehydrogenase to Induce Mitochondrial Stress and Suppress Oxidative Phosphorylation in Acute Myeloid Leukemia. | Cancer Res | 2024 | https://conductscience.org/library/papers/38266099 | PubMed |
| 38185524 | [Efficacy analysis of selinexor combined with hypomethylating agent in the treatment of refractory/relapsed acute myeloid leukemia exposed to venetoclax]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | https://conductscience.org/library/papers/38185524 | PubMed |
| 38049328 | [The development of selective XPO1 inhibitors in the treatment of acute myeloid leukemia]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | https://conductscience.org/library/papers/38049328 | PubMed |
| 38026089 | Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes. | Immunotargets Ther | 2023 | https://conductscience.org/library/papers/38026089 | PubMed |
| 37880950 | The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell Lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response. | Technol Cancer Res Treat | 2023 | https://conductscience.org/library/papers/37880950 | PubMed |
| 37601075 | Real-world experience with selinexor-containing chemotherapy-free or low-dose chemotherapy regimens for patients with relapsed/refractory acute myeloid leukemia and myeloid sarcoma. | Front Pharmacol | 2023 | https://conductscience.org/library/papers/37601075 | PubMed |
| 37195589 | Update on Small Molecule Targeted Therapies for Acute Myeloid Leukemia. | Curr Treat Options Oncol | 2023 | https://conductscience.org/library/papers/37195589 | PubMed |
Genes32
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/30596398
GET https://conductscience.org/api/papers/v1/30596398/references?page=2